Milestone Scientific Announces Commercial Rollout of CompuFlo® Epidural System at iHeal Pain Center Following Medicare Price Assignment
Milestone Scientific Inc. (NYSE: MLSS) announced the commercial rollout of its CompuFlo® Epidural System at iHeal Pain Center following successful epidural steroid injection (ESI) procedures. This marks the launch of Milestone's next phase of commercial activities after achieving a granted Medicare Part B Physician payment rate for the system under CPT code CPT0777T.
The company also reported a robust pipeline of clinics in trials across multiple states through its partnership with Axial Biologics. The Medicare Price Assignment was granted across several Jurisdictional Medicare Administrative Contractors (JMAC) regions, including key states like Florida, Texas, and Pennsylvania.
Arjan Haverhals, CEO of Milestone Scientific, expressed satisfaction with the Axial Biologics partnership and the positive feedback from clinicians. The company is actively providing demos and performing procedures at numerous clinics, aiming to convert them into long-term users of the CompuFlo® technology.
Milestone Scientific Inc. (NYSE: MLSS) ha annunciato il lancio commerciale del suo CompuFlo® Epidural System presso iHeal Pain Center, dopo aver effettuato con successo iniezioni epidurali di steroidi (ESI). Questo segna l'inizio della prossima fase delle attività commerciali di Milestone, dopo aver ottenuto un tasso di pagamento per medici delle Medicare Parte B per il sistema sotto il codice CPT CPT0777T.
La società ha anche riportato un pipeline solido di cliniche in fase di sperimentazione in vari stati grazie alla sua partnership con Axial Biologics. L'assegnazione del prezzo Medicare è stata concessa in diverse regioni degli appaltatori amministrativi Medicare giurisdizionali (JMAC), includendo stati chiave come Florida, Texas e Pennsylvania.
Arjan Haverhals, CEO di Milestone Scientific, ha espresso soddisfazione per la partnership con Axial Biologics e per i feedback positivi ricevuti dai medici. La società sta attivamente fornendo dimostrazioni ed eseguendo procedure in numerose cliniche, con l'obiettivo di convertirle in utilizzatori a lungo termine della tecnologia CompuFlo®.
Milestone Scientific Inc. (NYSE: MLSS) anunció el lanzamiento comercial de su CompuFlo® Epidural System en el iHeal Pain Center tras realizar con éxito procedimientos de inyección epidural de esteroides (ESI). Esto marca el inicio de la próxima fase de actividades comerciales de Milestone después de haber recibido un tasa de pago para médicos de Medicare Parte B para el sistema bajo el código CPT CPT0777T.
La compañía también informó de un sólido flujo de clínicas en pruebas en varios estados a través de su asociación con Axial Biologics. La asignación de precios de Medicare fue concedida en varias regiones de Contratistas Administrativos de Medicare Jurisdiccional (JMAC), incluyendo estados clave como Florida, Texas y Pennsylvania.
Arjan Haverhals, CEO de Milestone Scientific, expresó su satisfacción por la asociación con Axial Biologics y los comentarios positivos de los clínicos. La compañía está proporcionando activamente demostraciones y realizando procedimientos en numerosas clínicas, con el objetivo de convertirlas en usuarias a largo plazo de la tecnología CompuFlo®.
밀스톤 사이언티픽 Inc. (NYSE: MLSS)는 iHeal Pain Center에서 성공적인 경막외 스테로이드 주사(ESI) 절차 후 CompuFlo® Epidural System의 상업적 출시를 발표했습니다. 이는 CPT 코드 CPT0777T에 따라 시스템에 대한 메디케어 파트 B 의사 지급률을 승인받은 후 밀스톤이 상업 활동의 다음 단계에 들어섰음을 의미합니다.
회사는 Axial Biologics와의 파트너십을 통해 여러 주에서 시험 중인 클리닉의 강력한 파이프라인을 보유하고 있다고 보고했습니다. 메디케어 가격 할당이 플로리다, 텍사스, 펜실베이니아와 같은 주요 주를 포함한 여러 관할지 의료 관리 계약자(JMAC) 지역에서 승인되었습니다.
밀스톤 사이언티픽의 CEO인 아르얀 하버홀스는 Axial Biologics와의 파트너십 및 임상 의사들로부터의 긍정적인 피드백에 대해 만족을 표명했습니다. 회사는 여러 클리닉에서 시연을 제공하고 절차를 수행하며, 이들 클리닉을 CompuFlo® 기술의 장기 사용자로 전환하는 것을 목표로 하고 있습니다.
Milestone Scientific Inc. (NYSE: MLSS) a annoncé le lancement commercial de son CompuFlo® Epidural System au centre de douleur iHeal suite à des procédures réussies d'injection épidurale de stéroïdes (ESI). Cela marque le début de la prochaine phase des activités commerciales de Milestone après avoir obtenu un taux de paiement pour médecins de Medicare Part B pour le système sous le code CPT CPT0777T.
La société a également rapporté un pipeline solide de cliniques en essai dans plusieurs états grâce à son partenariat avec Axial Biologics. L'attribution des prix de Medicare a été accordée dans plusieurs régions de Contrats Administratifs Medicare Juridictionnels (JMAC), y compris des états clés comme la Floride, le Texas et la Pennsylvanie.
Arjan Haverhals, PDG de Milestone Scientific, a exprimé sa satisfaction concernant le partenariat avec Axial Biologics et les retours positifs des cliniciens. L'entreprise fournit activement des démonstrations et réalise des procédures dans de nombreuses cliniques, visant à les convertir en utilisateurs à long terme de la technologie CompuFlo®.
Milestone Scientific Inc. (NYSE: MLSS) gab die kommerzielle Einführung seines CompuFlo® Epidural Systems im iHeal Pain Center bekannt, nachdem erfolgreiche epidurale Steroidinjektionsverfahren (ESI) durchgeführt wurden. Dies markiert den Start der nächsten Phase der kommerziellen Aktivitäten von Milestone, nachdem ein Vergütungssatz für Ärzte der Medicare Teil B für das System unter dem CPT-Code CPT0777T genehmigt wurde.
Das Unternehmen berichtete auch über eine solide Pipeline von Kliniken, die in mehreren Bundesstaaten getestet werden durch die Partnerschaft mit Axial Biologics. Die Medicare-Preiszuweisung wurde in mehreren Regionen von Jurisdictional Medicare Administrative Contractors (JMAC) genehmigt, einschließlich wichtiger Bundesstaaten wie Florida, Texas und Pennsylvania.
Arjan Haverhals, CEO von Milestone Scientific, äußerte seine Zufriedenheit mit der Partnerschaft zu Axial Biologics und dem positiven Feedback von Klinikern. Das Unternehmen bietet aktiv Demos an und führt Verfahren in zahlreichen Kliniken durch, mit dem Ziel, diese in langfristige Nutzer der CompuFlo®-Technologie zu verwandeln.
- Successful adoption of CompuFlo® Epidural System at iHeal Pain Center
- Granted Medicare Part B Physician payment rate for CompuFlo® Epidural System
- Strategic partnership with Axial Biologics to accelerate adoption
- Robust pipeline of clinics in trials across multiple states
- Positive feedback from clinicians on the CompuFlo® system
- None.
Insights
The commercial rollout of Milestone Scientific's CompuFlo® Epidural System at iHeal Pain Center marks a significant milestone in the company's growth strategy. This adoption follows successful epidural steroid injection (ESI) procedures, demonstrating the system's clinical efficacy and potential for wider acceptance.
The recent Medicare Part B Physician payment rate granted for the CompuFlo® Epidural System under the CPT code CPT0777T is a important development. This pricing assignment across multiple Jurisdictional Medicare Administrative Contractors (JMAC) regions, including key states, significantly enhances the system's market potential and accessibility.
The strategic partnership with Axial Biologics appears to be accelerating adoption, with multiple customer pilots underway in states like New Jersey, Texas and Florida. This expansion strategy, combined with positive clinician feedback, suggests a promising outlook for increased market penetration.
However, investors should note that while initial adoption is encouraging, the long-term success will depend on consistent positive outcomes, continued clinician acceptance and the company's ability to scale its operations effectively.
The commercial rollout of the CompuFlo® Epidural System and the Medicare price assignment are positive developments for Milestone Scientific's financial outlook. The Medicare coverage across multiple regions significantly expands the potential market and could drive revenue growth.
With a market cap of
However, investors should consider that the company's ability to capitalize on these opportunities will depend on factors such as:
- Speed of adoption in new clinics
- Ability to manage production and distribution costs
- Potential competition in the market
While the news is positive, the company's small size makes it potentially volatile. Investors should monitor upcoming financial reports to assess the tangible impact of these developments on revenue and profitability.
Reports Robust Pipeline of Clinics in Trials Across Multiple States through Partnership with Axial Biologics
ROSELAND, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that iHeal Pain Center has adopted the CompuFlo® Epidural System following successful epidural steroid injection (ESI) procedures by Dr. Desai, DO. Dr. Desai has performed six cervical and two lumbar ESI procedures using the CompuFlo® Epidural System, leading to its integration within the clinic.
This milestone marks the launch of the next phase of Milestone Scientific's commercial activities, following the recent achievement of a granted Medicare Part B Physician payment rate with First Coast Service Options Inc. (FCSO) and Novitas Solutions, Inc. for the CompuFlo® Epidural System under the American Medical Association’s (AMA) technology-specific Category III CPT® code CPT0777T (real-time pressure-sensing epidural guidance system when used in conjunction with a primary ESI procedure). The favorable Medicare Price Assignment was granted across multiple Jurisdictional Medicare Administrative Contractors (JMAC) regions, including key states such as Florida, Texas, Pennsylvania, New Jersey, Maryland, Colorado, Oklahoma, Louisiana, Arkansas, Mississippi, New Mexico, District of Columbia, and Delaware.
In addition to the Medicare pricing, Milestone Scientific recently announced a strategic partnership with Axial Biologics aimed at accelerating the adoption of the CompuFlo® Epidural System. The iHeal Pain Center represents the first clinic added through this partnership, with multiple customer pilots underway in key states such as New Jersey, Texas, and Florida.
“We are extremely pleased with our partnership with Axial Biologics, which has already led to the successful integration of the CompuFlo® Epidural System at iHeal Pain Center,” stated Arjan Haverhals, CEO of Milestone Scientific. “The feedback we’ve received from clinicians has been positive, particularly following the recent Medicare price assignment. The clinical benefits of the CompuFlo® system are clear—it provides real-time feedback, increasing precision for providers while reducing complications and enhancing patient safety. We are working tirelessly, providing demos and performing procedures at numerous clinics. This robust pipeline gives us confidence in our ability to convert these clinics into long-term users of the technology.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2022. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ
What is the CompuFlo® Epidural System by Milestone Scientific (NYSE: MLSS)?
Has Milestone Scientific (NYSE: MLSS) received Medicare coverage for the CompuFlo® Epidural System?
Which pain center has adopted Milestone Scientific's (NYSE: MLSS) CompuFlo® Epidural System?
What partnership has Milestone Scientific (NYSE: MLSS) formed to accelerate adoption of the CompuFlo® Epidural System?
